Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Mantle-Cell 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Lymphoma, B-Cell 1Lymphoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × glofitamab × Clear all
NCT07453095 2026-04-17

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

Fondazione Italiana Linfomi - ETS

Phase 2 Not yet recruiting
41 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡